Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Business, Policy & Funding › Regulatory News & FDA Approvals › Baebies Newborn Screening Assays for Galactosemia, Biotinidase Deficiency Get CE Mark

Baebies Newborn Screening Assays for Galactosemia, Biotinidase Deficiency Get CE Mark

May 27, 2020
|
staff reporter

NEW YORK – Newborn and pediatric testing company Baebies said on Wednesday that its newborn screening assays for galactosemia and biotinidase deficiency have received the CE mark and are available in Europe and other geographies that recognize the CE mark.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
09
Featured Webinar

Navigating the FDA's EUA Process for Diagnostics in the Present and Future: A Stakeholder Panel Discussion

Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.

What's Popular?

In Regulatory News & FDA Approvals

  1. FDA Grants Emergency Use Authorization to Coronavirus Tests From Visby Medical, SNIBE

  2. CDC Reverses Position, Says Asymptomatic Patients Should Be Tested for SARS-CoV-2

  3. Roche Nabs CE Mark for SARS-CoV-2 Quantitative Antibody Test

  4. Roche Gets FDA Emergency Use Authorization for Rapid Coronavirus, Flu Test

  5. DiaSorin Receives CE Mark to Use Saliva Samples With COVID-19 Test

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.